SANTA CRUZ BIOTECHNOLOGY, INC.

FRMD7 siRNA (h): sc-91037

BACKGROUND

FERM domains are roughly 150 amino acids in length and are found in a number of cytoskeletal-associated proteins such as Ezrin, Radixin, Moesin and 4.1 (erythrocyte membrane protein band 4.1), where they provide a link between cytoskeletal signals and membrane dynamics. FRMD7 (FERM domain-containing protein 7) is a 714 amino acid protein containing one FERM domain. Localizing to cell projection, FRMD7 is expressed in liver, kidney and pancreas with low levels of expression found in heart and developing neural retina as well as adult and embryonic brain. FRMD7 plays a role in neurite development and may also contribute to the control of eye movement and gaze stability. Defects in FRMD7 have been linked to X-linked congenital nystagmus, an early onset disorder characterized by horizontal pendular oscillations of the eye and decreased visual acuity. FRMD7 exists as two isoforms due to alternative splicing events.

REFERENCES

1. Zhang, B., Liu, Z. and Zhao, G. 2007. Novel human pathological mutations. Gene symbol: FRMD7. Disease: congenital motor nystagmus. Hum. Genet. 122: 414.
2. Thomas, S., Proudlock, F.A., Sarvananthan, N., Roberts, E.O., Awan, M., McLean, R., Surendran, M., Kumar, A.S., Farooq, S.J., Degg, C., Gale, R.P., Reinecke, R.D., Woodruff, G., Langmann, A., Lindner, S., Jain, S., et al. 2008. Phenotypical characteristics of idiopathic infantile nystagmus with and without mutations in FRMD7. Brain 131: 1259-1267.
3. He, X., Gu, F., Wang, Z., Wang, C., Tong, Y., Wang, Y., Yang, J., Liu, W., Zhang, M. and Ma, X. 2008. A novel frameshift mutation in FRMD7 causing X-linked idiopathic congenital nystagmus. Genet. Test. 12: 607-613.
4. Li, N., Wang, L., Cui, L., Zhang, L., Dai, S., Li, H., Chen, X., Zhu, L., Hejtmancik, J.F. and Zhao, K. 2008. Five novel mutations of the FRMD7 gene in Chinese families with X-linked infantile nystagmus. Mol. Vis. 14: 733-738.
5. Li, N.D., Wang, L.M., Cui, L.H., Chen, X., Zhu, L.N., Guo, X. and Zhao, K.X. 2008. Study of gene mutation in a Chinese family with X-linked congenital nystagmus. Zhonghua Yan Ke Za Zhi 44: 138-142.
6. Self, J., Haitchi, H.M., Griffiths, H., Holgate, S.T., Davies, D.E. and Lotery, A. 2010. Frmd7 expression in developing mouse brain. Eye 24: 165-169.
7. Betts-Henderson, J., Bartesaghi, S., Crosier, M., Lindsay, S., Chen, H.L., Salomoni, P., Gottlob, I. and Nicotera, P. 2010. The nystagmus-associated FRMD7 gene regulates neuronal outgrowth and development. Hum. Mol. Genet. 19: 342-351.
8. Fingert, J.H., Roos, B., Eyestone, M.E., Pham, J.D., Mellot, M.L. and Stone, E. 2010. Novel intragenic FRMD7 deletion in a pedigree with congenital X-linked nystagmus. Ophthalmic Genet. 31: 77-80.
9. Thomas, M.G., Crosier, M., Lindsay, S., Kumar, A., Thomas, S., Araki, M., Talbot, C.J., McLean, R.J., Surendran, M., Taylor, K., Leroy, B.P., Moore, A.T., Hunter, D.G., Hertle, R.W., Tarpey, P., Langmann, A., Lindner, S., et al. 2011. The clinical and molecular genetic features of idiopathic infantile periodic alternating nystagmus. Brain 134: 892-902.

CHROMOSOMAL LOCATION

Genetic locus: FRMD7 (human) mapping to Xq26.2.

PRODUCT

FRMD7 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 µM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see FRMD7 shRNA Plasmid (h): sc-91037-SH and FRMD7 shRNA (h) Lentiviral Particles: sc-91037-V as alternate gene silencing products.

For independent verification of FRMD7 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-91037A, sc-91037B and sc-91037C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 µl of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 µl of RNAse-free water makes a 10 µM solution in a 10 µM Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

FRMD7 siRNA (h) is recommended for the inhibition of FRMD7 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor FRMD7 gene expression knockdown using RT-PCR Primer: FRMD7 (h)-PR: sc-91037-PR (20 µl). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.